SERINA THERAPEUTICS

Serina Therapeutics CEO Steven A. Ledger will present on continuous drug delivery for Parkinson's disease at Tribe Public’s webinar on Dec 18, 2024. The discussion will focus on Serina’s IND candidate for continuous dopaminergic stimulation (CDS) to reduce motor complications in advanced Parkinson’s patients.

Serina Therapeutics CEO Steven A. Ledger to present at Tribe Public’s webinar on continuous drug delivery for Parkinson's disease, discussing the company’s IND candidate and its potential to reduce motor complications in advanced Parkinson’s patients.

Serina Therapeutics' Chief Development Officer, Randall Moreadith, presented at the 3rd Annual LNP Immunogenicity & Toxicity Summit on Serina's POZ-lipid, which showed no IgM or IgG antibody responses in animal models, contrasting with standard PEG-lipids that elicit such responses, potentially leading to safer LNP formulations.

Serina Therapeutics secured $10M equity financing from JuvVentures to advance SER-252 into Phase 1 trials for advanced Parkinson's disease patients in H2 2025, issuing 1M shares at $10/share, a 120% premium to the November 26 closing price, with funds delivered in two $5M tranches.

Serina Therapeutics granted 60,500 stock options to three new non-executive employees on Nov. 6, 2024, to align interests with shareholders and promote business success, under its 2024 Inducement Equity Plan.

Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, PhD, presents at the 14th Annual Injectables Summit in Boston on partnering with Enable Injections to deliver advanced Parkinson's Disease therapeutics via the enFuse wearable drug delivery platform.

Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, Ph.D., to present at the 4th Annual mRNA-Based Therapeutics Summit on July 29, 2024, in Boston, MA, discussing strategies to overcome anti-PEG antibody responses in mRNA-LNP formulations.